Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib plus tislelizumab in metastatic uveal melanoma with liver metastases
2021-002474-99Phase 2Active
- Sponsor
- Gem
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sitravatinib and tislelizumab in intraocular melanoma, sponsored by Gem. Primary endpoint: Objective response rate. Started May 2022; status: active.
02
Drugs
sitravatinibtislelizumab
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2021-002474-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002474-99.